A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

Lignende værker

• Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
  af: Farlow, Martin R., et al.
  Udgivet: (2015)
• Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
  af: Micca, Joseph L, et al.
  Udgivet: (2014)
• Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
  af: Molinuevo, José L, et al.
  Udgivet: (2015)
• Predictors of Sustained Response to Rivastigmine in Patients With Alzheimer's Disease: A Retrospective Analysis
  af: Sadowsky, Carl H., et al.
  Udgivet: (2011)
• Rivastigmine From Capsules to Patch: Therapeutic Advances in the Management of Alzheimer’s Disease and Parkinson’s Disease Dementia
  af: Sadowsky, Carl H., et al.
  Udgivet: (2014)